Invivyd (IVVD) Announces Favorable Phase 3 Analysis for VYD2311 COVID-19 Treatment [Yahoo! Finance]
Invivyd, Inc. (IVVD)
Company Research
Source: Yahoo! Finance
in its REVOLUTION clinical program, specifically regarding VYD2311, a monoclonal antibody candidate for COVID-19 prevention. A pre-specified analysis of the Phase 3 DECLARATION study revealed that accumulated clinical events already provide sufficient statistical power to support high-end efficacy targets. Consequently, Invivyd has triggered a conservative upsizing of the study by ~500 subjects to ensure robust data across various scenarios. This adjustment is expected to shift the timing of top-line results slightly, moving from mid-year guidance to Q3 2026. In addition to its COVID-19 efforts, the company revealed the discovery and advancement of VMS063, a novel monoclonal antibody for the treatment and prevention of measles. Designed to be a first-in-class precision therapy, VMS063 targets the measles Fusion protein to prevent cell entry, demonstrating high potency against circulating lineages in laboratory assays. With US measles incidence reaching decade-high levels, Invivyd
Show less
Read more
Impact Snapshot
Event Time:
IVVD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IVVD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IVVD alerts
High impacting Invivyd, Inc. news events
Weekly update
A roundup of the hottest topics
IVVD
News
- Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care SummitGlobeNewswire
- Invivyd Updates VYD2311 REVOLUTION Trials, Modestly Upsizes Study, Unveils Measles mAb VMS-063 [Yahoo! Finance]Yahoo! Finance
- Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of MeaslesGlobeNewswire
- Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune HealthGlobeNewswire
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
IVVD
Earnings
- 3/5/26 - Miss
IVVD
Sec Filings
- 4/9/26 - Form 8-K
- 4/6/26 - Form ARS
- 4/6/26 - Form DEFA14A
- IVVD's page on the SEC website